Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase І /II trial

Soyoung Baek, Choung-Soo Kim, Sung-Bae Kim, Yong-man Kim, Seog-Woon Kwon, YongMan Kim, HyunSoo Kim, Hyunah Lee

J Transl Med. 2011 Oct 20;9(1):178. 

Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma

Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon C, Jung CW

Clin Immunol. 2007 Dec;125(3):257-67. Epub 2007 Oct 3

Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.

Matsumoto A, Haraguchi K, Takahashi T, Azuma T, Kanda Y, Tomita K, Kurokawa M, Ogawa S, Takahashi K, Chiba S, Kitamura T.

Int J Urol. 2007 Apr;14(4):277-83.

Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.

Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E.

J Immunother. 2007 Jan;30(1):116-22.

Antigen-independent immune responses after dendritic cell vaccination.

Leonhartsberger N, Ramoner R, Putz T, Gander H, Rahm A, Falkensammer C, Bartsch G, Thurnher M.

Cancer Immunol Immunother. 2007 Jun;56(6):897-903. Epub 2006 Nov 15.

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M.

Cancer Immunol Immunother. 2005 Jul;54(7):663-70. Epub 2004 Dec 17.

Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.

Arroyo JC, Gabilondo F, Llorente L, Meraz-Ríos MA, Sánchez-Torres 

J Clin Immunol. 2004 Jan;24(1):86-96.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.

Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Ruecker A, Müller S,Sauerbruch T, Schmidt-Wolf IG.

Cancer Immunol Immunother. 2002 Dec;51(11-12):637-44. Epub 2002 Oct 3.

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.

Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T.

Cancer Immunol Immunother. 2002 Mar;51(1):45-52. Epub 2002 Jan 10.